Test description
Some families may have an increased risk of developing certain types of cancer through the inheritance of harmful changes (pathogenic variants) in certain genes.
Testing for these genetic variants can determine whether a patient might be at increased risk of developing cancer and suggest an appropriate prevention or surveillance strategy.
The genes analysed in this panel, ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM, are all high and medium high risk genes for breast, ovarian and/or colorectal cancer.
- Pre-test genetic counselling session
- Genetic testing of 16 high and medium high risk genes
- Post-test genetic counselling session
Test information
BRAoVO™ Breast/Ovarian Genetic Testing & Counselling Package (GP Request)
To determine presence or absence of germline variant for hereditary breast and ovarian cancer
ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM
Massively Parallel Sequencing
Including two counselling sessions, 7 - 9 weeks
No
$1299
Cancer genetics request form - GP Only preferred. Standard pathology form accepted.
Blood x 2
EDTA
Pre- and post-test genetic counselling is mandatory and included in the package.